Papers
1
Total Citations
3
H-Index
1
About
Koichi Tamano is a pioneering figure in the automation of cancer biomarker diagnostics, with his work centered on improving the clinical utility of glycoprotein assays. His primary research focuses on the lectin-antibody enzyme immunoassay of the alphafetoprotein (AFP) carbohydrate chain, specifically the AFP-L3 fraction—a critical tumor marker for hepatocellular carcinoma. Tamano’s major contribution lies in refining this complex assay for seamless integration with enzyme immunoassay robots, a breakthrough that enhances reproducibility and throughput in clinical labs. By enabling the simultaneous detection of AFP-L3 and total AFP using two distinct lectins, his 2005 study (3 citations) laid the groundwork for automated, high-precision liver cancer screening. Though his citation count is modest, the practical impact of his work is significant: it addresses a key bottleneck in cancer diagnostics, moving a specialized manual technique toward routine automation. This achievement underscores Tamano’s dedication to bridging the gap between advanced biomarker research and real-world clinical application, making him a notable contributor to the field of automated immunoassay technology.
Research Focus
Key Achievements
Top Papers
- 1